KLOW combines GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg. Its individual components have been studied separately in extracellular-matrix, cellular-migration, tendon-repair and inflammatory-signalling models. No direct clinical study has established the effects or safety of this exact combined formulation.

RESEARCH BASIS

GHK-Cu study · BPC-157 study · TB-4 study · KPV study

RESEARCH DISCLAIMER

This product is supplied strictly for laboratory research purposes only. The information above summarizes published research and does not represent medical advice or establish safety or effectiveness for human or veterinary use.